Cristi Condoiu

Dr. Cristi Condoiu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
CCCristi Condoiu
Cristi Condoiu
ABAdelina Băloi
Adelina Băloi
Dorel SandescDorel Sandesc
Dorel Sandesc
ACAlin Adrian Cumpanas
Alin Adrian Cumpanas
SLSilviu Constantin Latcu
Silviu Constantin Latcu
RBRazvan Bardan
Razvan Bardan
Background/Objectives: Despite multiparametric MRI (mpMRI)-guided biopsy, clinically significant upgrading (CSU) of ISUP Grade Group (GG) at radical prostatectomy (RP) remains common in prostate cancer (PCa). We aimed to identify predictors of CSU (biopsy GG ≤ 2 to RP GG ≥ 3) using routine preoperative variables, and to benchmark a parsimonious logistic model against multiple machine learning (ML) classifiers. Methods: In this single-center exploratory analysis, 96 consecutive PCa patients underwent pre-biopsy mpMRI, systematic ± MRI-targeted biopsy, and RP. Predictive modeling was restricted to biopsy GG 1–2 patients (n = 64). LASSO-guided feature selection and Firth-penalized logistic regression were used to build a locked reference model, evaluated against ML classifiers using cross-validated discrimination, calibration, and decision curve analysis. Results: CSU occurred in 10/64 patients (15.6%). Positive core ratio was the dominant independent predictor (adjusted OR 1.54 per 10% increase, 95% CI 1.10–2.17). PSA density (PSAD) showed a consistent positive association but did not retain independent significance. The locked two-variable model (AUC ≈ 0.75–0.79) outperformed all ML classifiers in discrimination, calibration, and net clinical benefit; however, the limited event count (n = 10) constrains model stability, and these findings require external validation. Conclusions: In a PCa mpMRI-informed diagnostic pathway, CSU is primarily driven by biopsy tumor burden. A simple logistic model based on positive core ratio and PSAD outperformed more complex ML approaches in this exploratory cohort, supporting integration of biopsy tumor burden metrics into preoperative risk stratification pending external validation.

26 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
DNDorin Novacescu
Dorin Novacescu
ABAdelina Băloi
Adelina Băloi
SLSilviu Constantin Latcu
Silviu Constantin Latcu
Flavia BadercaFlavia Baderca
Flavia Baderca
Dorel SandescDorel Sandesc
Dorel Sandesc
ACAlin Adrian Cumpanas
Alin Adrian Cumpanas
Background/Objectives: Renal cell carcinoma (RCC) with venous tumor thrombus (VTT) extending into the inferior vena cava (IVC) occurs in 4–10% of patients and represents one of the most technically demanding scenarios in urologic surgery. Open radical nephrectomy with en bloc thrombectomy remains the gold standard for infradiaphragmatic disease (Mayo Levels 0–III), offering the only realistic prospect for long-term cure. This narrative review provides a technically oriented, evidence-based guide for surgical urologists managing these complex cases. Methods: PubMed/MEDLINE, Scopus, and Web of Science were searched (1970–March 2025) using terms related to RCC, venous tumor thrombus, IVC thrombectomy, and perioperative management. Priority was given to prospective studies, systematic reviews, large retrospective cohorts, and current guidelines (EAU 2025, NCCN v2.2024). Original intraoperative photographs supplement procedural descriptions. Results: We detail the complete perioperative pathway: VTT classification (Mayo/AJCC), multimodal imaging, patient optimization, and level-specific open surgical techniques—ranging from Satinsky clamping for Level 0–I thrombi to full piggyback liver mobilization with hepatic vascular exclusion for Level III disease. Contemporary perioperative mortality is <2% at high-volume centers (reported in single and multicenter retrospective series from high-volume institutions), with 5-year cancer-specific survival of approximately 50–60% in non-metastatic cases. Adjuvant pembrolizumab is now a standard of care following the KEYNOTE-564 trial. Neoadjuvant immune checkpoint inhibitor plus tyrosine kinase inhibitor combinations show promising VTT downstaging rates (44–100%), though their role remains investigational. Robotic-assisted thrombectomy demonstrates favorable perioperative outcomes for Level I–II thrombi at experienced centers. Conclusions: Open surgery remains the cornerstone of curative treatment for RCC with infradiaphragmatic VTT, requiring meticulous preoperative planning and multidisciplinary collaboration at high-volume centers. Integration of perioperative systemic therapies and robotic-assisted approaches holds promise for further improving outcomes in this challenging patient population.

5 February 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
CCCristi Condoiu
Cristi Condoiu
MMMihael Musta
Mihael Musta
ACAlin Adrian Cumpanas
Alin Adrian Cumpanas
RBRazvan Bardan
Razvan Bardan
VDVlad Dema
Vlad Dema
DNDorin Novacescu
Dorin Novacescu
Background: Bladder cancer (BC) is a heterogeneous malignancy, and predicting response to immune checkpoint inhibitors (ICIs) remains a challenge. Herein, we investigate a high-risk bladder tumor, which developed during anti-BRAF/MEK therapy for a concurrent advanced BRAF-V600E-positive malignant melanoma (MM) and subsequently underwent complete spontaneous necrosis following Nivolumab immunotherapy, only to recur thereafter while still under the same treatment. This unique scenario provided an opportunity to investigate the roles of BRAF gene mutations in BC pathogenesis, respectively, of PD-L1 expression in immunotherapy response prediction. Methods: We retrospectively analyzed BC specimens obtained via transurethral resection at two critical time-points: prior to the complete spontaneous necrosis under Nivolumab (prenecrosis) and after tumor recurrence postnecrosis (postnecrosis). The BRAF gene mutation status was evaluated using quantitative polymerase chain reaction (qPCR). PD-L1 expression was assessed by immunohistochemistry (IHC), quantified using the combined positive score (CPS), and a cutoff of ≥10 for positivity. Results: Neither pre- nor postnecrosis BC samples harbored BRAF gene mutations. Prenecrosis PD-L1 expression (CPS = 5) indicated a minimal likelihood of response to immunotherapy. However, complete spontaneous necrosis occurred under Nivolumab, followed by recurrence with further reduced PD-L1 expression (CPS = 1). Conclusions: The complete BC regression challenges the conventional role of PD-L1 as a sole predictive biomarker for immunotherapy. This study also highlights the potential role of BRAF/MEK inhibitors in BC oncogenesis and underscores the need for alternative biomarkers, such as tumor mutation burden (TMB) and circulating tumor DNA (ctDNA), to guide treatment selection in BC better.